---
layout: minimal-medicine
title: Idarucizumab
---

# Idarucizumab
### Generic Name
Idarucizumab

### Usage

Idarucizumab is a specific antidote used to reverse the anticoagulant effects of dabigatran.  Dabigatran is a medication used to prevent blood clots, often prescribed for conditions like atrial fibrillation and venous thromboembolism (blood clots in the veins). Idarucizumab is used in emergency situations where rapid reversal of dabigatran's effects is critical. This includes:

* **Urgent surgery or procedures:** When a patient needs surgery or a procedure and the anticoagulant effects of dabigatran need to be quickly reversed to minimize bleeding risk.
* **Life-threatening or uncontrolled bleeding:** In cases of severe bleeding where dabigatran's anticoagulant action is contributing to the dangerous blood loss.


### Dosage

**Adult Dosage (Dabigatran Reversal):**

The recommended dose is 5 g, administered intravenously (IV) as two separate 2.5 g doses given no more than 15 minutes apart.  An additional 5 g dose *may* be considered in some situations, though its efficacy isn't fully established and should only be used under careful medical supervision.

**Pediatric Dosage:**

The safety and efficacy of idarucizumab in children have not been established.  It should not be used in pediatric patients.

**Dosage Adjustments:**

No dosage adjustments are currently recommended based on hepatic (liver) or renal (kidney) impairment according to the manufacturer's prescribing information.


### Side Effects

**Common Side Effects (1-10%):**

* Headache
* Constipation
* Nausea

**Less Common, but Serious Side Effects (<1%, post-marketing and/or case reports):**

* Hypersensitivity reactions (allergic reactions)
* Acute ischemic stroke
* Circulatory shock
* Deep vein thrombosis
* Intracardiac thrombus (blood clot within the heart)
* Multi-organ failure
* Myocardial infarction (heart attack â€“ specifically non-ST-elevation myocardial infarction, NSTEMI)
* Pulmonary edema (fluid in the lungs)
* Pulmonary embolism (blood clot in the lungs)
* Right heart failure

**Important Note:**  If you experience any side effects, especially serious ones, seek immediate medical attention.


### How it Works

Idarucizumab is a humanized monoclonal antibody fragment. This means it's a laboratory-made protein designed to bind very specifically to dabigatran (and its metabolites).  It works by competitively binding to dabigatran with a much higher affinity than thrombin (a clotting factor). By binding to dabigatran, idarucizumab effectively neutralizes its anticoagulant effect, allowing normal blood clotting to resume.  This reversal occurs within minutes of administration.


### Precautions

* **Contraindication:** Idarucizumab is contraindicated (should not be used) in patients with known hypersensitivity (allergic reaction) to idarucizumab or any components of its formulation.

* **Increased Risk:**  Patients treated with dabigatran often have underlying conditions that increase their risk of thromboembolic events (blood clots). Reversing dabigatran's effect increases this risk; therefore, anticoagulant therapy should be resumed as soon as clinically appropriate.

* **Use with Caution:** Idarucizumab should be used cautiously in patients with cardiovascular or cerebrovascular disorders (diseases affecting the heart and blood vessels or brain and blood vessels).  Caution is also advised during breastfeeding, as excretion in breast milk is unknown.

* **Pregnancy:** The safety of idarucizumab during pregnancy is not established.


### FAQs

* **Q: How quickly does idarucizumab work?**  A: Idarucizumab works rapidly, neutralizing the anticoagulant effects of dabigatran within minutes of administration.

* **Q:  Is idarucizumab a long-term treatment?** A: No, idarucizumab is used only in emergency situations to reverse the effects of dabigatran temporarily. It is not a continuous medication.

* **Q: What should I do if I experience side effects?** A: Contact your doctor or seek immediate medical attention if you experience any side effects, especially those that are severe or concerning.

* **Q: How is idarucizumab administered?** A: Idarucizumab is administered intravenously (IV) as a bolus injection.  Specific instructions should be followed as provided by your healthcare provider.

* **Q: How is idarucizumab stored?** A: Refer to the product packaging for specific storage instructions.

**Disclaimer:** This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or altering any medication, including idarucizumab.  This information is not a substitute for professional medical advice.
